Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution

• Published in: Journal of medicinal chemistry Vol. 57; no. 5; pp. 1770 - 1776
• Main Authors: Moreau, Benoît, O’Meara, Jeff A., Bordeleau, Josée, Garneau, Michel, Godbout, Cedrickx, Gorys, Vida, Leblanc, Mélissa, Villemure, Elisia, White, Peter W., Llinàs-Brunet, Montse
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 13-03-2014
• Subjects: Crystallography, X-Ray; Humans; Liver - metabolism; Magnetic Resonance Spectroscopy; Protease Inhibitors - chemistry; Protease Inhibitors - pharmacokinetics; Protease Inhibitors - pharmacology; Spectrometry, Mass, Electrospray Ionization; Viral Nonstructural Proteins - antagonists & inhibitors
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/jm400121t

Given the emergence of resistance observed for the current clinical-stage hepatitis C virus (HCV) NS3 protease inhibitors, there is a need for new inhibitors with a higher barrier to resistance. We recently reported our rational approach to the discovery of macrocyclic acylsulfonamides as HCV protease inhibitors addressing potency against clinically relevant resistant variants. Using X-ray crystallography of HCV protease variant/inhibitor complexes, we shed light on the complex structural mechanisms by which the D168V and R155K residue mutations confer resistance to NS3 protease inhibitors. Here, we disclose SAR investigation and ADME/PK optimization leading to the identification of inhibitors with significantly improved potency against the key resistant variants and with increased liver partitioning.